Ayala Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Dec '23 Dec 31, 2023	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	0.01	0.01	0.69
Revenue Growth (YoY)	-	-98.12%	-
Cost of Revenue	0.01	0.01	0.6
Gross Profit	-	-	0.09
Selling, General & Admin	11.19	11.19	9.74
Research & Development	24.08	24.08	27.85
Operating Expenses	35.27	35.27	37.59
Operating Income	-35.27	-35.27	-37.5
Other Non Operating Income (Expenses)	-15.72	-15.72	0.07
EBT Excluding Unusual Items	-50.98	-50.98	-37.43
Merger & Restructuring Charges	-1	-1	-
Pretax Income	-51.98	-51.98	-37.43
Income Tax Expense	-3.91	-3.91	0.58
Net Income	-48.07	-48.07	-38.01
Net Income to Common	-48.07	-48.07	-38.01
Shares Outstanding (Basic)	6	6	3
Shares Outstanding (Diluted)	6	6	3
Shares Change (YoY)	-	107.90%	-
EPS (Basic)	-7.99	-7.99	-13.13
EPS (Diluted)	-7.99	-7.99	-13.13
Free Cash Flow	-29.49	-29.49	-34.51
Free Cash Flow Per Share	-4.90	-4.90	-11.92
Gross Margin	-	-	13.01%
Operating Margin	-271276.92%	-271276.92%	-5419.51%
Profit Margin	-369784.62%	-369784.62%	-5493.21%
Free Cash Flow Margin	-226807.69%	-226807.69%	-4986.99%
EBITDA	-34.9	-34.9	-37.34
D&A For EBITDA	0.37	0.37	0.16
EBIT	-35.27	-35.27	-37.5

Source: S&P Capital IQ. Standard template. Financial Sources.